Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD-tamoxifen pharmacokinetic interaction study in primary breast cancer
NL-OMON52942Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of cannabidiol and tamoxifen in breast cancer (2 cohorts), sponsored by Erasmus MC. Primary endpoint: Endoxifen AUC0-24h. Started Nov 2020; status: active, not recruiting.
02
Drugs
cannabidioltamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON52942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52942.